identifying risk factors for severe covid-19 in patients with aml, mds and all
Published 2 years ago • 46 plays • Length 3:35Download video MP4
Download video MP3
Similar videos
-
4:45
covid-19 risk factors in patients with hematologic malignancies
-
5:56
features of covid-19 infection in hematology patients
-
3:16
impact of covid-19 on aml treatment & management
-
1:55
diagnosing and treating aml: the role of mutational profiling
-
2:31
management of all patients during covid-19
-
2:01
impact of comorbidities on patient selection for combination therapies in cll
-
56:57
hematopathology: flow cytometry and acute leukemias
-
1:01:07
understanding diagnostic & biomarker testing | lrf webinars
-
9:57
lymphocytic choriomeningitis virus: information for medical professionals
-
1:46
personalized treatments to manage post-transplantation outcomes in aml: insights from morpho
-
1:37
a phase i/ii trial of seclidemstat in combination with azacitidine for patients with mds and cmml
-
1:07
how covid-19 has impacted clinical practice and treatment approaches in multiple myeloma
-
7:28
mbg453 with hypomethylating agents in aml and high-risk mds
-
1:37
a phase ii trial evaluating e7820 in patients with aml with splicing factor mutations
-
4:39
aml & mds: mac or ric?
-
2:16
current and future treatment approaches for hr-mds
-
1:11
genomic testing can help identify patient risk factors and guide clinical decision-making
-
6:31
a meta-analysis assessing the safety of cytoreductive therapies in younger patients with pv
-
2:23
factors to consider when selecting jak inhibitors for patients with mf
-
5:42
immune checkpoint inhibitors in mds and aml
-
4:09
key considerations for community physicians in the management of secondary aml
-
1:33
all diagnostics: challenges and considerations